Ion Beam Applications SA

Brussels Stock Exchange IBAB.BR

Ion Beam Applications SA Net Income Margin for the year ending December 31, 2023: -2.12%

Ion Beam Applications SA Net Income Margin is -2.12% for the year ending December 31, 2023, a -226.74% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Ion Beam Applications SA Net Income Margin for the year ending December 31, 2022 was 1.68%, a 35.27% change year over year.
Ion Beam Applications SA Net Income Margin for the year ending December 31, 2021 was 1.24%, a -87.89% change year over year.
Ion Beam Applications SA Net Income Margin for the year ending December 31, 2020 was 10.23%, a 279.93% change year over year.
Ion Beam Applications SA Net Income Margin for the year ending December 31, 2019 was 2.69%, a 257.53% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Brussels Stock Exchange: IBAB.BR

Ion Beam Applications SA

CEO	Mr. Olivier Legrain
IPO Date	Jan. 4, 2000
Location	Belgium
Headquarters	3, Chemin du Cyclotron
Employees	1,943
Sector	Technology
Industries 3D Printing Biotechnology Chemicals & Advanced Materials Composite Materials Hardware & Electronics Medical Instruments Nuclear Plastics

Description

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Key trends

Past 5 years